Full-Time

Vice President Commercial Sales

Progyny

Progyny

501-1,000 employees

Fertility benefits management for employers

Compensation Overview

$175k - $185k/yr

+ Bonus + Equity + 401(k) match

No H1B Sponsorship

Remote in USA

Remote

Must be based in the United States; travel up to 30% is required.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Sales
CRM
Salesforce

Get referred to Progyny

See people who can refer or advise you

Requirements
  • At least 8 years of experience selling healthcare benefits, healthcare technology, or point solutions to large employer groups.
  • Demonstrated success working with or selling through national benefits consulting firms and advisors that influence employer purchasing decisions.
  • A proven track record of consistently achieving and exceeding enterprise sales quotas.
  • Strong consultative selling, negotiation, presentation, and closing skills.
  • Executive presence with the ability to build credibility and influence senior decision-makers.
  • Written and verbal communication skills sufficient to deliver compelling presentations in in-person and virtual environments.
  • Ability to build trusted relationships and influence stakeholders at all levels of an organization.
  • Experience using Salesforce customer relationship management software for pipeline management, forecasting, and opportunity tracking.
  • Ability to work in a fast-paced, collaborative, and results-oriented environment.
  • Passion for improving access to family building benefits and advancing innovative healthcare solutions.
  • Must be willing to travel up to 30% for client meetings, industry conferences, and internal meetings.
  • Must be authorized to work in the United States without current or future sponsorship.
Responsibilities
  • Develop and execute a strategic territory plan to build a robust pipeline and consistently exceed annual sales goals.
  • Identify, qualify, negotiate, and close new business opportunities with employer groups using a consultative sales approach.
  • Serve as a trusted advisor to benefits executives, healthcare consultants, brokers, and other key stakeholders by understanding their business priorities and aligning Progyny's solutions to their needs.
  • Become a subject matter expert on Progyny's Family Building solution and deliver compelling presentations and product demonstrations to prospective clients.
  • Build and maintain strong relationships with benefits consultants and other market influencers to generate new opportunities and accelerate sales.
  • Gather customer and market feedback and partner with internal teams to help shape commercial strategy and product evolution.
  • Collaborate cross-functionally with Marketing, Client Success, Product, and Implementation teams to ensure a seamless customer experience.
  • Maintain an accurate sales pipeline and forecast using Salesforce customer relationship management software.
  • Stay informed on market trends and the competitive landscape to effectively position Progyny's differentiated value proposition.
Desired Qualifications
  • A Bachelor's degree in Business, Marketing, Communications, or a related field.

Progyny is a fertility benefits manager that partners with employers to offer comprehensive fertility and family-building services to employees. It provides a wide range of services including IUI, IVF, fertility preservation, adoption assistance, and surrogacy support, all integrated into employers’ existing benefits packages. The company makes money by signing contracts with employers, typically using a fixed-fee or per-employee-per-month pricing model, and it works to deliver better clinical outcomes to reduce overall treatment costs. Unlike broader health insurers, Progyny focuses specifically on fertility care and family-building, emphasizing measurable clinical results and seamless workflow within the benefits ecosystem. Its goal is to expand access to inclusive fertility benefits while improving outcomes and controlling costs for employers and employees.

Company Size

501-1,000

Company Stage

IPO

Headquarters

New York City, New York

Founded

2008

Get referred to Progyny

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $350.5 million, up 11% excluding the transition client.
  • Management reaffirmed 2026 revenue of $1.36 billion to $1.385 billion after strong sales momentum.
  • Progyny repurchased 1.2 million shares for $31.5 million, signaling confidence and supporting EPS.

What critics are saying

  • Q3 2026 guidance assumes softer summer engagement, exposing fragile utilization seasonality.
  • A former large client already cut 2025 revenue by $48.5 million, showing renewal risk.
  • Carrot, Maven, Kindbody, and health-plan bundles pressure Progyny’s pricing; one lost enterprise account hurts fast.

What makes Progyny unique

  • Progyny’s Smart Cycle model bundles fertility care, medications, and concierge navigation for employers.
  • Its contracted clinic network concentrates volume, supporting 25.5% gross margin in Q2 2026.
  • Zero debt and $236.9 million cash give Progyny unusual balance-sheet flexibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Company Equity

401(k) Retirement Plan

401(k) Company Match

Performance Bonus

Family Planning Benefits

Fertility Treatment Support

Wellness Program

Mental Health Support

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Yahoo Finance
Aug 12th, 2026
2 cash-heavy stocks to watch and 1 to avoid

Two healthcare companies with strong cash positions are attracting investor attention, whilst a fertility benefits provider faces challenges. Progyny holds $214.4 million in net cash, representing 14.2% of its market capitalisation. However, the company has struggled with underwhelming unit sales over the past two years and demonstrates below-average returns on capital. Trading at $27.95 per share, Progyny commands a 13.9x forward price-to-earnings ratio. Molina Healthcare maintains a net cash position of $1.22 billion, or 11.9% of market cap. The managed healthcare provider has achieved 13.7% annual revenue growth over five years, outpacing sector averages. Operating across 21 states, Molina serves low-income individuals through Medicaid, Medicare, and Marketplace programmes. Axos Financial, a digital banking and financial services company, holds $39.48 million in net cash, though this represents just 0.7% of its market capitalisation.

Market Wire News
Aug 7th, 2026
Progyny, Inc. to present at the Canaccord Genuity Annual Growth Conference.

Progyny, Inc. to present at the Canaccord Genuity Annual Growth Conference. August 07, 2026 10:51:30 am NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) - Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 3:30 p.m. ET. Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny's investor relations website at http://investors.progyny.com. About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. Market Wire News envision a world where everyone can realize their dreams of family and ideal health. Its outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians. Its benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain's Fast 50 for NYC. For more information, visit www.progyny.com. For Further Information, Please Contact: Investors: James Hart [email protected] Media: Alexis Ford [email protected]

Yahoo Finance
Aug 7th, 2026
Progyny hits record EBITDA with revenue up 11%, repurchases $31.5M in shares

Progyny reported record quarterly revenue and adjusted EBITDA for Q2 2026. Second quarter revenue rose 5.3% year-over-year, or 11% excluding contributions from a large former client under a transition agreement in Q2 2025. The fertility benefits provider's gross margin expanded 180 basis points year-over-year, driven by efficiencies in care management and service delivery. Operating cash flow reached more than $50 million for the fourth time in five quarters. Progyny repurchased nearly 1.2 million shares for $31.5 million during the quarter under its $200 million programme. Since November, the company has bought back 10.8 million shares, reducing shares outstanding by approximately 12.5%. The company projects full-year 2026 revenue between $1.36 billion and $1.385 billion, representing growth of 5.5% to 7.5%.

Mining Press Releases
Aug 7th, 2026
Progyny, Inc. to present at the Canaccord Genuity Annual Growth Conference.

Progyny, Inc. to present at the Canaccord Genuity Annual Growth Conference. NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) - Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 3:30 p.m. ET. Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny's investor relations website at http://investors.progyny.com. About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain's Fast 50 for NYC. For more information, visit www.progyny.com. For Further Information, Please Contact: Investors: James Hart [email protected] Media: Alexis Ford [email protected] Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Yahoo Finance
Aug 6th, 2026
Progyny beats Q2 revenue expectations but drops guidance, stock falls 10%

Fertility benefits company Progyny reported second-quarter results for 2026, with revenue of $350.5 million, beating analyst expectations by 0.6% and representing 5.3% year-on-year growth. The company's non-GAAP earnings per share of $0.55 also exceeded estimates by 6.2%. Despite the positive quarterly results, Progyny's stock dropped 10.2% following disappointing forward guidance. The company's revenue forecast for the next quarter of $340 million came in 3% below analyst estimates. Progyny also lowered its full-year revenue guidance to $1.37 billion from $1.39 billion, a 0.9% decrease. Chief Executive Officer Pete Anevski attributed the strong quarterly results to member engagement trending toward the higher end of expectations.